drugset / Trial / NCT00392002

Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

NCT00392002

Phase 4 Completed 2000 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

To characterize the burden of disease in GERD patients of prescription therapy'

Timeline

Start
2005-10
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg
Subject Esomeprazole Small molecule 40 mg